Profund Advisors LLC Reduces Holdings in Insmed, Inc. $INSM

Profund Advisors LLC lowered its position in Insmed, Inc. (NASDAQ:INSM) by 39.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,558 shares of the biopharmaceutical company’s stock after selling 12,539 shares during the quarter. Profund Advisors LLC’s holdings in Insmed were worth $1,968,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in INSM. Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. ORG Partners LLC boosted its position in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 196 shares during the period. Hilltop National Bank purchased a new position in shares of Insmed during the second quarter valued at approximately $28,000. FNY Investment Advisers LLC bought a new position in shares of Insmed during the second quarter valued at approximately $33,000. Finally, LRI Investments LLC purchased a new stake in shares of Insmed in the second quarter worth approximately $59,000.

Insider Activity

In related news, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the transaction, the insider directly owned 54,902 shares of the company’s stock, valued at $10,089,889.56. This trade represents a 33.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO William Lewis sold 6,865 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the sale, the chief executive officer owned 233,924 shares of the company’s stock, valued at approximately $30,035,841.60. This represents a 2.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 179,787 shares of company stock valued at $26,428,149. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on INSM shares. Jefferies Financial Group boosted their price objective on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. The Goldman Sachs Group boosted their target price on shares of Insmed from $196.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Truist Financial upped their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. Stifel Nicolaus lifted their price objective on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Finally, Wells Fargo & Company boosted their price objective on shares of Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.29.

Insmed Stock Performance

INSM stock opened at $191.92 on Tuesday. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $197.08. The business has a 50-day moving average price of $158.44 and a 200 day moving average price of $117.58. The company has a market capitalization of $40.93 billion, a P/E ratio of -33.61 and a beta of 1.05. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the previous year, the company earned ($1.27) earnings per share. The firm’s revenue was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.